Month: June 2024

Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model Rejuva also prevented weight and glycemic rebound after semaglutide withdrawal Data provide first demonstration that Rejuva treatment has potential to mimic natural release of GLP-1 from pancreas BURLINGTON, Mass., June 23, 2024 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today presented new data from its preclinical Rejuva pancreatic gene therapy program in an oral presentation at the American Diabetes Association (ADA)’s 84th Scientific Sessions in Orlando, FL. The presentation titled “Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains...

Full analysis of body composition data showed class-leading lean mass preservation with 21.9% of weight loss attributable to lean mass and 78.1% attributable to fat GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate, in obesity, including the results of a recently completed body composition analysis, at the American Diabetes Association’s (ADA) 84th Scientific Sessions. “We’re pleased with the data presented at ADA that highlight the impressive lean mass preservation achieved with pemvidutide, with only 21.9% of weight loss attributable to lean mass,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of...

FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8 Bagsværd, Denmark, 23 June 2024 – Novo Nordisk announced results from the phase 3 FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment (regular treatment to prevent prolonged and spontaneous bleeding) with the investigational treatment Mim8. The data were presented at the International Society of Thrombosis and Haemostasis Annual Congress (ISTH 2024) in Bangkok, Thailand. In the trial population with no prior prophylaxis treatment:Mim8 demonstrated a superior reduction in the estimated mean annualised bleeding rate (ABR) of treated bleeds by...

Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and cardiovascular disease risk GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), on cardioinflammatory lipids at the American Diabetes Association’s (ADA) 84th Scientific Sessions. “Dyslipidemia is one of the most significant co-morbidities of obesity, impacting up to 70% of patients with obesity,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “These data add to the differentiated profile of pemvidutide and reinforce...

Casino Group has signed an agreement with Rocca and Auchan Retail France for the sale of its subsidiary Codim 2 Paris, 22 June 2024 Casino Group announces today that it has signed a unilateral purchase agreement for the sale of Codim 2, which operates 4 hypermarkets, 9 supermarkets, 3 cash & carries and 2 drive-throughs in Corsica, with sales of 332 million euros excluding taxes in 2023. As part of the sale, Rocca Group has undertaken to take over all the stores, which will be operated under the Auchan banner, as well as all Codim 2 store and head office employees. Completion of the sale is expected to take place after consultation with employee representative bodies and subject to clearance by the competent competition authorities.          *** This press release has been prepared for information purposes only and should not be construed...

Afrezza®Afrezza® (insulin human) Inhalation Powder.Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17% with usual care and 24% had time-in-range (TIR) above 70% with no increased hypoglycemia compared with 13% with usual care More than 50% of subjects at the end of the study expressed an interest in continuing to use Afrezza®DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 22, 2024 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung...

VANCOUVER, British Columbia, June 21, 2024 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on Thursday, June 20, 2024. A total of 845,972,994 common shares were voted at the Meeting, representing 64.75% of the votes attached to all outstanding common shares. Shareholders voted overwhelmingly in favour of all items of business before the Meeting. The eight director nominees listed in B2Gold’s Management Information Circular (the “Circular”) dated May 8, 2024, were elected as directors of B2Gold to hold office for the ensuing year or until their successors are elected or appointed. Detailed results of the vote for each director are set out below:Name Total...

CALGARY, Alberta, June 21, 2024 (GLOBE NEWSWIRE) — Carbeeza Inc. (“Carbeeza” or the “Company“) (TSXV:AUTO) (OTCQB: CRBAF) announces today that it has received a Statement of Claim filed by Northern Micro Inc. and IDX Systems Corp. in the amount of approximately $2,175,000, claimed in connection with alleged unpaid professional services and related matters. Carbeeza intends on defending the Statement of Claim. Carbeeza Inc.Carbeeza is a Canadian-based software company whose platform is targeted to the automotive marketplace. It is the first application to harness the power of Artificial Intelligence to accurately predict the best financing scenario for consumers, all while keeping the consumer anonymous. Using state-of-the-art technology, Carbeeza brings the process of buying a car right to the phone, tailor-made...

GONZALES, La., June 21, 2024 (GLOBE NEWSWIRE) — Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the “Company”) today announced that it intends to release the results of its operations for the fourth quarter and full year of fiscal 2024 before the market opens on Friday, June 28, 2024. Olivia W. Elliott, President and Chief Executive Officer and Craig J. Demarest, Vice President and Chief Financial Officer, will host a teleconference at 8:00 a.m. Central Daylight Time on that day to discuss the Company’s results and answer appropriate questions. Interested individuals may join the teleconference by dialing (844) 861-5504 and asking to join the Crown Crafts, Inc. call. The teleconference can also be accessed in listen-only mode by visiting the Company’s website at www.crowncrafts.com. The financial information to be discussed during the teleconference...